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Executive Summary 
 
The internship report  includes the process of reviewing and evaluating a company’s financial statements 
(such as the Balance Sheet or Income Statement), thereby gaining an understanding of the financial health 
of the company and enabling more effective decision making. 
 
Financial statement analysis is an evaluative method of determining the past, current and projected 
performance of a company. Techniques are commonly used as part of financial statement analysis like 
ratio analysis, which calculates statistical relationships between data.  
 
Financial statement forecasting enables organizations to assess their current operating performance, 
review the state of the economy and determine how they will perform in the future. Understanding that an 
ounce of prevention is worth a pound of cure, corporate management fully supports forecasting activities. 
Top leadership's support is cardinal because it favors acceptance down the hierarchical spectrum, 
especially when it comes to predicting the results of segments with weaker sales data. 
 
This internship report is aimed at providing a comprehensive analysis of the financial statements of GSK. 
Efforts have been employed to make the content relevant, reliable and understandable. 
 
The report has been segmented into five parts. These are basically Introduction, Organization and 
Industry Analysis, Activities within GSK Bangladesh Ltd., Trend Analysis of Financial Statement and 
Conclusion.  
I have taken all the reasonable care to ensure the quality of the report and I hope that it includes all the 
necessary information which is in the scope of my ability. 
 
I would like to express that my effort for this report will provide you a better picture regarding the subject 
matter of the study. 
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                                                                                       1.0   Introduction 
The organization part fully covers the detailed information of GlaxoSmithKline and its 
operations in Bangladesh Market. It covers the mission, strategy of the company and the 
organizational structure or the organ gram as well as the departments of the company. Moreover 
I tried to figure out its market position and the SWOT analysis of the company. 
                                                                                                                                                                                         1.1Objective of the study 
1.1.1 General Objective  
The general objective of the study is to fulfill the partial requirement of the Graduation under 
the Bachelor of Business Administration program of BRAC University as per university policy. 
1.1.2 Specific Objective 
 To be more specific, this study entails the Financial Trend Analysis of GlaxoSmithKline 
Bangladesh Limited to figure out and observe the financial performance of GSK BD Ltd. over 
the past 5 years. 
                                                                                                1.2 Scope of the study 
Defining the scope of the study is a broad aspect to be described. Still the Secretarial & Finance 
Department helped me a lot to prepare the report. On the other hand due to some confidential 
resolutions there were difficulties to find out some information as well.    
                                                                                                         1.3 Methodology 
1.3.1 Data Collection 
To bring out the study two types of data have been used- 
 Primary Data 
 Secondary Data 
Details are as follows- 
 Primary Data: To collect all these data, I had to commence an interview with the 
Finance Manager & Secretarial Executive who could give the actual information that 
was required to prepare an authentic report. 
 Secondary Data: Referring to the secondary sources I mainly used the web site of 
GlaxoSmithKline Bangladesh Ltd. and also other organizational documents that I could 
manage to study on the purpose of preparing the report. 
 GSK Bangladesh Ltd. Financial Performance Trend Analysis 2 
 
                                                                                                                                                                             1.4 Limitation of the study 
  Preparing such intense report, requires huge amount of information. While preparing this 
report, many limitation and hindrance have been faced to going on further. Still I managed to 
bring up the best within my access limit. The limitations those I confronted mostly are- 
 The major hindrance that I faced was, GSK authority was unwilling to share or 
disclose some information which was really required to prepare the report due to 
confidential issues. 
 
                                                                                 2.0 GlaxoSmithKline 
 GlaxoSmithKline (GSK) is a world’s leading research-based pharmaceutical company with a 
powerful combination of skills and resources that provides a platform for delivering strong 
growth in today’s rapidly changing healthcare environment. 
GSK has leadership in four major therapeutic areas- anti invectives, central nervous system 
(CNS) and respiratory & gastro- intestinal/ metabolic. In addition it is a leader in the important 
areas of vaccines and has growing portfolio of oncology products. 
GSK supplies products to 140 global markets and has over 100,000 employees worldwide. GSK 
has 180 manufacturing site in 41 countries.  
  
 
 
 
 
 
                                                                                                                                                                                                                                                             2.1 History of GlaxoSmithKline 
In 1973 
The company was oriented as Joseph Nathan & Company in New Zealand with the founding of a 
small import export company. It started its operation as a processing unit of abundant fresh milk 
of New Zealand. The only product it was producing was Glaxo Baby Food.  
In 1875 
It started to export baby food to UK Alec Nathan, son of Joseph Nathan, coined the name Glaxo 
from Glactose. 
In 1924 
Joseph Nathan & Company entered the pharmaceutical industry with the manufacture of Ostelin, 
the first Vitamin D preparation. The importance of the pharmaceutical market was soon realized 
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and in 1935, Glaxo Laboratories Limited was founded with its headquarters at Greenford, 
Middlesex and London for the production and marketing of foods and pharmaceuticals. 
In 1947 
After the 2
nd
 world war, Glaxo developed rapidly. Glaxo Laboratories Limited absorbed its 
parent Joseph Nathan & Company, and became a public company in 1947. 
In 1963 
Edinburgh Pharmaceutical Industries Limited, which owned Duncan, Flockhart and Company 
Limited and MAC Farlane Smith Limited, joined Glaxo.       
In 1995 
Glaxo acquired 100% share, of Wellcomes PLC on may 01, 1995 and formed Glaxo Wellcome 
PLC. 
In 1998 
Glaxo Wellcome achieved a number of regulatory milestones for several of its key projects, such 
as ZEFFIX for the treatment of influenza. 
In 2000 
Glaxo Wellcome and SmithKlineBeechman merged to form GlaxoSmithKline; a worldwide 
research based pharmaceutical company. 
GlaxoSmithKline is the only British organization in the world’s top 20 pharmaceutical 
companies. Subsidiary companies are established over 50 countries of the world many with their 
own manufacturing facilities and the group have agency representation in more than 100 offices.     
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                                                                      2.2 GlaxoSmithKline Bangladesh Limited 
GlaxoSmithKline Bangladesh Limited is a subsidiary of GlaxoSmithKline Plc; world’s leading 
research based pharmaceutical company. One of its strong strength is its powerful combination 
of skills and resources that provides a platform to deliver fastest growth In today’s rapidly 
changing healthcare environment. The principle activities of the company are manufacturing and 
marketing of pharmaceutical, vaccines and healthcare products. 
GlaxoSmithKline conducts the operational activities in Bangladesh as a principal with its own 
set-up of manufacturing, marketing and distribution. The company has started business in 
Bangladesh in 1969 at Chittagong by importing products from group company. 
 
In 1969 
A supporting factory of Glaxo Laboratories (Pakistan) Limited was founded in Chittagong. 
In 1974 
Glaxo Bangladesh Ltd. was incorporated as a company in Bangladesh. 
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In 1996 
It has been incorporated as Glaxo Wellcome Bangladesh Ltd. 
 
In 2002 
It has been incorporated as GlaxoSmithKline Bangladesh Limited. 
 
The Chittagong factory of GlaxoSmithKline Bangladesh Limited is considered as the Center of 
Excellence in Global manufacturing & supply network of the group. In Bangladesh GSK held 6
th
 
position in pharmaceutical industry having market share of 5.2% (as of September 2002) 
occupying strong hold in key therapeutic areas like Respiratory, Dermatology, Anti- infective 
and Vaccines. Brand names of some major products of the company are: Ventolin Inhaler, 
Ceoprex, Zinnat, Parapyrol, Zantac, Piriton, Dextrose and Engerix –B etc. on the other hand, in 
terms of consumer goods GSK is doing business by manufacturing Horlicks, Boost, Viva, 
Maltova etc.        
 
2.2.1 Operations in Bangladesh 
Headquarter 
GlaxoSmithKline Bangladesh Limited 
Corporate Office 
House # 2A, Road # 138. 
Gulshan-1. 
 
Registered Office & Factory 
Fouzderhat Industrial Area 
North Kattali, Chittagong.  
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District Marketing Office 
GlaxoSmithKline Bangladesh Limited has eleven District Marketing Offices (DMO) throughout 
the country. These are divided in five zones by which GSK’s products are sold. 
 
Zone DMO 
Dhaka Dhaka, Mymensing 
Chittagong Chittagong, Maijdee 
Comilla Comilla, Sylhet 
Bogra Bogra, Rajshahi, Rangpur 
Barisal Barisal, Jessore 
Table 1: List of DMOs 
 
2.2.2 GlaxoSmithKline Bangladesh Ltd. (In Market Place) 
 Total Market Share: Tk.. 140 Crore (2011) 
  Market Share: 1.95 % (2011) 
 Ranking: 12 (2011) 
 
2.2.3 Share Information GlaxoSmithKline Bangladesh Ltd.  
 Share Price Tk.. 10 each 
  Total No. of Authorized Share 20,000,000 
  Authorized Share Capital Tk.. 20,000,000 
 Market Capitalization 6920.685 (Million) 
 
2.2.4 Banking Operation of GlaxoSmithKline Bangladesh Ltd. 
In 2010, GSK transacted its banking operations through: 
 SCB 
 HSBC   
 Citi Bank NA 
 Agrani Bank 
 Sonali Bank 
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                                      2.3 GlaxoSmithKline- Mission, Strategic Intent & Spirit 
 
2.3.1  Mission 
The mission statement of the business- “ Our global quest is to improve the quality of human life 
by enabling people to do more, feel better and live longer” 
 
2.3.2  Strategic Intent 
“Our strategic intent states our business goal” - We want to become the indisputable leader in 
our industry.  
 
2.3.3  Spirit 
“Our company spirit describes how we need to behave if we are to achieve our goal” – We 
undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for 
innovation. We value performance achieved with integrity. We will attain success as a world 
class global leader with each and every one of our people contributing with passion and 
unmatched sense of urgency. 
 
2.3.4  Corporate Strategies 
 Quality and Customer acceptance – Achieve business vision through quality and 
customer acceptance by providing safe & effective medicine. 
 Good manufacturing practice – Strictly maintained GMP (Good Manufacturing 
Practice) 
 Customer focus- A respective quality throughout 
 The entire organization or each operating unit and company 
 All processes, systems and services product design and development, through 
manufacture, supply and marketing 
 Compliance – With regulatory requirements, corporate quality requirements, group 
products and other applicable standards. 
 Added value – Through Continuous improvements and error- prevention to benefit 
customers and company 
 Dedicated Human resources – Develop a pool, of dedicated human resources through 
regular training. 
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2.3.5  Quality Statement 
Quality is the heart of everything we do- from the discovery of the module, through product 
development, manufacture, supply and sale; and is vital to all the service that supports our 
business performance. 
 
 Commitment 
- The health and safety of global operations. 
- Stewardship of our products. 
- Delivering competitive business advantage. 
 Responsibility 
- The health and safety of employees, contractors, visitors. 
- The protection of the environment and communities. 
- Compliance with laws and GSK standards. 
 
GlaxoSmithKline in time 
- Every second, more than 30 doses of vaccines are distributed by GSK. 
- Every minute, more than 1,100 prescriptions are written for GlaxoSmithKline. 
- Every hour, GSK spends more than US $ 450,000 to find new products. 
- Every day, more than 200 million people around the world use a GSK toothbrush or 
toothpaste. 
- Every hour, GSK donates more than US $ 148 million in cash and products to 
communities around the world.  
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                                       2.4 GlaxoSmithKline Bangladesh Limited Organ Gram 
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                       2.5 Functional Department of GlaxoSmithKline Bangladesh Ltd.  
GlaxoSmithKline Bangladesh limited comprises of six major departments. Those are as follows:- 
 Marketing 
 Human Resources 
 Finance & Accounts 
 Technical and Medical Regulatory Affairs 
 Information Technology 
Each department at GSK operates in different aspects but they are inter-related and complement 
each other. The main functions of these departments are shown bellow:- 
 
2.5.1  Marketing 
Department Head: Mr. Shamim Rabbani (Commercial Director) 
» Designing and implementing Sales Strategy 
» Controlling and updating distribution network 
» Providing marketing information services 
» Carrying out different awareness programs 
» Controlling international trades. 
» Building up public communication network. 
» Conducting market surveys as required. 
 
2.5.2  Human Resources 
Department Head: AKM Firoz Alam (HR Director) 
» Recruiting and training the best pool of employees needed for the company. 
» Managing smooth work flow in the organization. 
» Managing demands of the labors in the factory. 
» Allocating annual holidays. 
» Arranging the employee motivational programs. 
» Looking after the wage structure and waivers.  
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2.5.3  Finance & Accounts 
Department Head: Mr. Sarwar Azam Khan (Company Secretary & Finance Director) 
» Controlling the accounts. 
» Completing the annual budgets. 
» Allocating all kinds of payments to the staffs and managers. 
» Looking after all the revenues and expenses. 
» Conducting internal audit. 
» Keeping records through IT. 
» Facilitating local production cost. 
 
2.5.4  Technical   
» Producing precise amounts of products as per the year plan. 
» Ensuring total quality management. 
» Following good manufacturing practice. 
» Implementing raw material management. 
» Procuring and allocating assets efficiently. 
» Prioritizing best possible observations over the finished goods. 
 
2.5.5  Medical Regulatory Affairs 
» Liaison with government for legal issues. 
» Communicate with doctors and handling advertisement. 
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                                                                                                2.6 Industry Analysis  
In Bangladesh, the pharmaceutical sector is one of the fastest growing sectors.. In 2008 the total 
size of the pharma market in Bangladesh was estimated to be USD 700 million and is growing at 
a steady rate. The pharmaceutical sector is the second highest contributor to the National Ex-
Checker and the largest white collar labor intensive employment sector of the country. There are 
245 registered pharmaceutical manufacturing companies in Bangladesh. The local 
pharmaceutical manufacturers cater to about 97% of the internal demand. 
 
Today, Bangladesh Pharmaceutical Industry is successfully exporting APIs and a wide range of 
products covering all major therapeutic classes and dosage forms to 71 countries. Beside regular 
forms like; Tablets, Capsules & Syrups, Bangladesh is also exporting high-tech specialized 
products like HFA Inhalers, CFC Inhalers, Suppositories, Nasal Sprays etc. are also being 
exported from Bangladesh, and have been well accepted by the Medical Practitioners, Chemists, 
Patients and the Regulatory Bodies of all the importing nations. The packaging and the 
presentation of the products of Bangladesh are comparable to any international standard and 
have been accepted by them. 
 
The Pharma Industry of Bangladesh is now on the verge of entering highly regulated overseas 
markets like USA and Europe. In this connection, several pharmaceutical manufacturers have 
already made huge investments in their new state of art manufacturing facilities 
 
2.6.1  Dominant Economic Characteristics of The Industry 
The dominant economic characteristics are the factors that influence the overall operations of the 
players in it. The following table is the summary of the factors:- 
► Market size                                                 ► Product Characteristics                       
► Scope of competitive rivalry                      ► Presence of learning effects 
 ► Market growth rate                                    ► Industry profitability 
       ► Life cycle stage                                            
 ► Target & end consumers 
       ► Type of distribution channel used 
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Factors Description 
1. Market size Taka 7,186 Crore 
2. Scope of competitive rivalry National. In some case it is regional 
3. Market growth rate 5% to 7% annually on an average 
4. Life cycle stage Mature, continuous research does not let the 
curve decline 
5. Target customer & end consumers The doctors are the target customer & the end 
consumers are the general people 
6. Type of distribution channel used Wholesaler and retailer. In some cases (like 
vaccines) it is done through special outlet 
7. Product Characteristics Standardized and no scope of customization 
8. Presence of learning effects Yes, especially in drug research and 
formulation 
9. Industry profitability Above par, ultimately it is affected by the state 
of national economy. 
Table 2: Summary of the key factors 
 
2.6.2  GSK’S Market Share & Position 
Year Market Share Position 
2006 3.34% 12 
2007 2.90% 12 
2008 2.91% 12 
2009 2.24% 12 
2010 1.95% 12 
Table 3: GSK’s Market Share & Position 
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2.6.3  GSK’S Market Share & Position Comparison 
Top 12 Pharmaceutical Company’s Comparison 
Companies Market share Ranking 
SQUARE 19.18% 1 
INCEPTA PHARMA 9.05% 2 
 BEXIMCO 8.62% 3 
OPSONIN PHARMA 4.94% 4 
 ESKAYEF  4.84% 5 
 RENATA 4.73% 6 
ACME  4.44% 7 
A.C.I. 4.08% 8 
 ARISTOPHARMA 3.99% 9 
DRUG INTERNATIONAL 3.75% 10 
 SANOFI AVENTIS 2.57% 11 
GLAXOSMITHKLINE 1.95% 12 
Table 4: GSK’s Market Share & Position  
 
 
 
 GSK Bangladesh Ltd. Financial Performance Trend Analysis 15 
 
2.6.2  Porter’s five forces 
The five forces analysis is done on the basis of the most important 5 driving forces of the 
industry. While doing the analysis, information gathered in the previous table is used. The most 
important points that will determine the outcome of the analysis are: 
 Slow market growth due to the low purchasing power of the end consumers. 
 Exit barrier of the industry is very high due to high investment.  
 Specialization knowledge for the technology and research is must for a player. 
 No actual substitutes for pharmaceutical products are available.  
 
 
 
Figure 1: Industry Analysis 
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 The players are big and powerful enough to influence input cost. 
 Suppliers are chosen on a competition basis. 
 Many brands for the same products are available in the market. 
 End consumers are not really aware of the quality of the products. 
 Direct marketing of the products is illegal as per government rules. 
 
So the summary of the entire analysis refers to the scenario which is as such: 
 
Industry Analysis - At a glance 
Forces Position 
Threat of potential entry Very low 
Threat of substitute products Very low 
Bargaining power of the suppliers Very low 
Bargaining power of the buyers Very high 
Rivalry among the competitors Moderate to High 
 Table 5: Industry Analysis at A Glance 
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                                                                                 2.7 SWOT  Analysis  
SWOT is the acronym for Strengths, Weaknesses, Opportunities and Threats. It is an analytical 
framework to help summarize in a quick and concise way the risk and opportunities for any 
company across the value chain. A good SWOT should look into internal and external factors 
affecting the issue at hand.  
- Factors pertaining to the internal environment of the company. These are usually 
classified as Strengths (S) or Weaknesses (W)  
- Factors that pertaining to the external environment of the company. These are 
classified as Opportunities (O) or Threats (T).  
2.7.1  Strengths 
 Considerable financial resources to grow the business. 
 A widely recognized company with an attractive customer base. 
 Ability to take advantage of economies of scale. 
 Renowned for better quality products. 
 Follows GMP- Good Manufacturing practices. 
 Product innovation skill. 
 Proprietary technology and important patents. 
 Efficient, capable and honest work force. 
 Goodwill of the company. 
2.7.2  Weaknesses 
 Higher overall unit cost relatively to key competitors. 
 Weaker dealer or distribution network than key rivals. 
 Underutilized plant capacity. 
 Group compliance. Due to group policy, the company has to import raw materials from 
UK rather from neighboring countries (other than those which are procured locally) 
resulting in higher cost of production. 
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2.7.3  Opportunities 
 Target and acquire an untapped market for vaccines. 
 Expanding geographic coverage and product segment. 
 Expanding the company’s product line to meet a broader range of customer needs. 
 Alliances- company manufacturing that expands the firm’s market coverage and 
competitive capability. 
2.7.4  Threats 
 Slowdowns in the market growth. 
 Adverse shifts in foreign exchange rates and trade policies of governments. 
 Increasing threats from local competitors. 
 Costly new regulatory requirements. 
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                                                                                             2.8 Overall Assessment 
On the basis of overall organization part, we can clearly see that GlaxoSmithKline is one of the 
leading pharmaceutical companies in the world. The company is also doing sound business in 
Bangladesh for a long time. Still one major issue that strike to my eyes while doing the study is- 
GSK Bangladesh Limited is in the 12
th
 position in the Bangladeshi pharmaceutical industry 
according to the market share. So, they should obviously be careful for improving this situation 
as it used to be stand on the 5
th
 position in 2003.  
 
                                                                                                2.9 Recommendation 
 
 Promotional activities should be stronger. Improvement in this line will help GSK to have 
competitive advantage over their competitors and also to change the current market share 
position. 
 GSK should focus on reducing per unit cost in producing their product as GSK’s product 
is much more expensive than it’s competitors. 
 Distribution channels are still not well enough compare to its competitors. So, they 
should obviously be take care on improving distribution network.  
 GSK should be careful on copyrights matters as other companies are copywriting GSK’s 
products. 
 Marketing department should be very much careful on maintaining the 4 P’s properly as 
till now most of the problems come out from the 4 P’s sector. 
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                                                                       3.0   Activities within GSK 
 
While doing the internship program, so far the activities I did and the activities I learned from 
asking others from my curiosity referring from the other departments than that off Secretarial & 
Legal Department, I tried to put those knowing here at my best. 
 
 
 
 
                                                                                                       3.1 Work Related 
 
3.1.1  Tax deduction 
Paying authority deduct the Taxes it is rule of government. When buyer, buying something, like 
raw material, packing material and GSK cuts the TDS, payers should follow the same role where 
transaction must be occur within financial year, July to June. These roles will be accepted for 
every organization against with transaction. 
 1 lac - 2lac = 0% 
 2 lac -5 lac = 1% 
 5 lac -15 lac = 2.5% 
 15 lac -25 lac = 3.5 % 
 25 lac -3crore = 4 % 
 Above -3crore = 5 % 
This rule is applicable for every individual Account payable within financial year. 
 
3.1.2  Verifying the expense claims 
Every month, GSK confronts with a numerous numbers of expense claims which GSK is 
supposed to disburse as per company policy. The policy refers theses payments as allowance to 
the employees. There are two types of expense claims and those are- 
- Travelling Expense 
- Medical Expense 
 This is what something which is allowed for all the employees including Corporate Office, GMS 
Factory and DMO or field as well. 
But in terms of medical policy, GSK’s allowance is available for the employee’s spouse and 
children as well up to a certain age until or unless he/ she is not a minor. 
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 There are some costs which are known as Remuneration which are allowed for the Managers 
of the Corporate Office and DMO. Aside from these remunerations the Directors are the main 
receiver of the remuneration from the company. 
The claims are supposed to be verified with priority basis in every month as it is an audit issue. 
 
3.1.3  T &E Forms 
The expense claims of the Corporate Office and GMS factory are supposed to be sent through 
T&E Forms. 
This form allows employees to place their claims for further approval from their Bosses and as 
soon as the Boss gives the approval, Secretarial Legal Department goes for further processing. 
 
3.1.4  Final settlements 
If any of the employees leave GSK or gets terminated by GSK, Secretarial Department arranges 
a document known as Final Settlement Copy, which refers to keep the document as evidence for 
both the parties acknowledging that GSK don’t have any claim with the person any more neither 
do the party. 
 
 3.1.5  Payroll activities 
Though there is the HR and Accounts departments in GSK but the payroll is always been made 
by the Secretarial & Legal department as there are few issues that are required to be checked. 
 
3.1.6  Employee information database/software 
Secretarial & Legal, Human Resources and Finance & Accounts Department, all these three 
departments used to work in software named Vista 3P which may be referred as employee 
database system as well. 
 
3.1.7  Unison reporting 
 Each and every month GSK need to submit group report and internal report. Unison is a system 
where GSK Bangladesh Ltd. needs to submit report and this system control by the parents 
company. 
How many item share with group. 
 Financial position 
 Profit and loss sharing  
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This system contains unique code for every transaction. Before submission all debit item are 
positive, credit sign are negative must need to given 
3.1.8  Closing stock submission  
Value of the closing stock must retain at the value equivalent to Taka. When it comes to the 
question of submission in Unison system then it needs to convert the value at thousand. 
 
                                                                                              3.2 Organization Wide 
 
3.2.1 Prepare budget 
The budget is prepared on an annual basis in GSK and detailed by quarters, and then by months 
within those quarters. As we know a company can either follow a continuous budget or a zero 
based budget process. In case of zero based budgeting all costs are required to be justified is if 
die programs involved are being proposed for the first time. GSK Bangladesh follows a 
continuous budget process, which is an ongoing twelve-month budget that is created by the 
addition of a new budget month (twelve months in the future) as each current month expires; also 
known as a rolling budget. 
How much activity done by the management reporting manager related with budget 
 
 1. Calculation profit and loss and total turnover of GSK Bangladesh Ltd 
 
2. Prepare income statement budget which head count how much will be profitable  
 
3. Sales budget analysis like actual sales, standard sales, percentage of total, percentage of 
total growth. 
4.Budget for every head count like manufacturing GMS, selling, distribution, marketing, 
medical, administration, consumer health. 
5. Capital expenditure budget like plant budget, machinery budget, IT budget, furniture 
budget, other appliance budget, transportation budget. 
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6. Summary of departmental expenses for each and every single moth also operating 
expenses. 
 
7. Summary of revenue expenditure like advertising promotion, financial statement, 
marketing, distribution, medical, admin also product revenue calculate based on month basis 
 
8. Product profitability statement calculation product price, standard cost and gross profit. 
 
9. Prepare production cost sheet based on budget volume, unit cost, quality requirement, 
total cost, percentage of loss, percentage of total production cost. 
 
3.2.2  Price fixation: 
Price of the imported material re –fixation, before change the price list reporting manager need to 
think, 
 Unit  
 Currency 
 Cost and future price 
 Duty and vat 
 Proposed MRP 
After everything completing need to approved by board of director and then launched new price 
set for imported product. 
 
3.2.3  Maximum retail price calculation:  
Calculation the MRP imported product, need to consider some factor like transfer price current , 
currency (USD/GBP), current exchange rate as per before exchange rate , new mark factor, 
current MRP, revised MRP , changing MRP , change in MRP percentage, gaining total profit , 
net gain. 
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                               4.0  GSK’s Financial Performance Trend Analysis 
                                                                            4.1 Activity Analysis (Short term) 
 
Short Term Activity Ratios 
Ratio 2006 2007 2008 2009 2010 
Inventory turnover 
ratio 
0.55 0.65 0.69 0.86 0.92 
Average no of days 
inventory in stock 667.58 557.84 526.50 423.64 398.87 
Receivable Turnover 
Ratio 
2.33 1.86 1.34 1.82 2.08 
Average no. of days 
receivable 
outstanding 
156.96 196.75 272.63 200.33 175.33 
Payable turnover 
ratio 
0.91 0.91 0.83 1.02 0.82 
Average no. of days 
payable outstanding 401.54 402.43 440.73 356.52 442.55 
Table 6: Short Term Activity Ratio Analysis 
 Calculation is given in appendices  
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4.1.1  Inventory Turnover Ratio 
 Inventory turnover ratio measures the efficiency of managing inventory in an organization. 
Higher ratio indicates better position of inventory. It means inventory does not remain in 
warehouse. This ratio measures how many times inventory turned over in a year. The operation 
of a firm starts with purchasing of raw materials and go through production process and 
production of finished goods. After completion of production process, finished goods are sold. 
This entire process is called inventory turnover. This ratio increased in 2010 which is 0.92. It 
indicates that during that period inventory management of the company became efficient. The 
ratio was lower in 2004-2005 which was 0.52 and then gradually it increased over years. 
 
Ratio 2006 2007 2008 2009 2010 
Inventory turnover 
ratio 
0.55 0.65 0.69 0.86 0.92 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
19.67 5.95 24.28 6.20 
  
 
Figure 2: Inventory Turnover Ratio 
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Comment 
 Higher is better. 
 GSK is performing well day by day. 
 
4.1.2   Average no of day’s inventory in stock ratio   
It measures for how many days inventory remain unsold. Lower the ratio is better. Inventory 
remains unsold for 705 days in 2005 which is not efficient. In year 2010 this ratio is reduced to 
399 days which refers to the increased efficiency. 
 
Ratio 2006 2007 2008 2009 2010 
Average no of days 
inventory in stock 667.58 557.83 526.50 423.64 398.87 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
-16.43 -5.61 -19.53 -5.84 
 
 
Figure 3: Average No of Days Inventory in Stock 
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Comment 
 Fewer numbers of days indicates the better situation 
 GSK is performing well day after day. 
 
4.1.3   Receivable Turnover Ratio 
This ratio shows how many times receivable is turned over in a year. Receivable turnover starts 
at the point where inventory turnover ends. Higher the ratio indicates the efficiency in credit 
management of a company. Here the receivable turnover ratio has increased over 2005 to 2006. 
In 2007 and 2008 the ratio declined and in 2010 it again increased 2.08 to which means 
receivable is collected almost 2 times in year 2010. 
 
Ratio 2006 2007 2008 2009 2010 
Receivable Turnover 
Ratio 
2.32 1.85 1.33 1.82 2.08 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
-20.22 -27.83 36.09 14.25 
 
 
Figure 4: Receivable Turnover Ratio 
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Comment 
 Higher turnover is better. 
 Credit policy has been changed by GSK by the year 2009 after the down fall at 2008. 
 Overall GSK is doing fair. 
 
4.1.4  Average No of Days Receivable Outstanding 
This ratio measures the number of days requires for collecting the receivable after selling 
inventory. Lower the ratio is better for the company. The ratio was 159.09 days in the year 2005. 
Then it decreased in 2006 to 157 days. Then in 2007 and 2008 it again increased to 197 days and 
273 days. In 2010 GSK required 175 days to collect the receivable, that means it again declined. 
 
Ratio 2006 2007 2008 2009 2010 
Average no. of days 
receivable 
outstanding 
156.96 196.75 272.63 200.33 175.33 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
25.35 38.56 -26.51 -12.47 
 
 
Figure 5: Average No of Days Receivable Outstanding 
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Comment 
 Fewer the days are the best. 
 GSK is performing great day by day though there is an inverse downfall in 2008.  
 
4.1.5   Payable Turnover 
This ratio measures that how many times payable is turned over in a year. It is a process which 
starts with purchasing of raw materials and ends with the payment of this. Lower the ratio is 
better because payables are turned over less frequently. So company gets time to pay its debts.  
The payable turnover ratio was 0.75 in 2005. In 2006 and 2007 the ration remain constant at 
0.91.  In year 2008 it decreased to 0.83. In 2009 it was 1.02 which was higher than rest 4 years. 
 
Ratio 2006 2007 2008 2009 2010 
Payable turnover 
ratio 
0.90 0.90 0.82 1.02 0.82 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
-0.22 -8.68 23.61 -19.43 
 
 
Figure 6: Payable Turnover 
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Comment 
 Lower turnover is the best 
 Consistency is maintained by GSK at a great extent.  
 
4.1.6   Average No. of Day’s Payable Outstanding 
This ration measures that, how many days company can defer its payment. Larger the time 
period is better for the company as company can make its’ payment lately. In 2005, the average 
number of days’ payable outstanding was 487 days. In 2006 and 2007 the ration remain constant 
at 402 days.  In year 2010 it increased to 442 days which was higher than rest of the previous  
years.  
 
Ratio 2006 2007 2008 2009 2010 
Average no. of days 
payable outstanding 401.53 402.43 440.72 356.52 442.55 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
0.22 9.51 -19.10 24.13 
 
 
Figure 7: Average No. of Day’s Payable Outstanding 
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Comment 
 Higher is better. 
 GSK is consistently trying to match the best. 
 
                                                                           4.2 Activity Analysis (Long term) 
 
Long Term Activity Ratios 
 
Ratios 2006 2007 2008 2009 2010 
Fixed asset turnover 
ratio  
 
4.29 4.71 5.49 8.23 9.31 
Total Asset Turnover 
ratio 
 
1.42 1.48 1.38 1.77 1.64 
Table 7: Long Term Activity Ratio Analysis 
 Calculation is given in appendices 
 
4.2.1  Fixed Asset Turnover Ratio 
 This ratio measures that, how efficiently firm manages its fixed asset. And higher ratio indicates 
efficiency of firm. The ratio is not stable over the years. The ratio decreased in year 2006 from 
4.62 to 4.30. It increased in year 2007, 2008, 2009 and 2010 to 4.72, 5.49, 8.23, and 9.31. It 
indicates the efficiency of the firm in managing it’s fixed assets. 
 
 
Ratios 2006 2007 2008 2009 2010 
Fixed asset turnover 
ratio  
 
4.29 4.71 5.49 8.23 9.31 
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% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
9.77 16.42 49.96 13.07 
 
 
Figure 8: Fixed Asset Turnover Ratio 
Comment 
 Higher is better. 
 GSK’s performance is great in this regard. 
 
4.2.2  Total Asset Turnover Ratio 
 Total asset turnover ratio measures the efficiency in managing total assets. Higher the ratio is 
better for the company. Here total asset turnover ratio has increased subsequently from year 2006 
to year 2007. In year 2008 the ratio declined to 1.39. In 2009 the ratio is higher at 1.78. It means 
firm is able to increase the efficiency in managing the total asset. 
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Ratios 2006 2007 2008 2009 2010 
Total Asset Turnover 
ratio 
 
1.42 1.48 1.38 1.77 1.64 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
4.46 -6.81 28.22 -7.69 
 
 
Figure 9: Total Asset Turnover Ratio 
Comment 
 Higher is better. 
 GSK is inconsistent regarding this factor. 
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                                                                                                  4.3 Liquidity Ratio 
 
Ratio 2006 2007 2008 2009 2010 
Current Ratio 
 
6.63 4.64 2.96 3.10 2.59 
Quick ratio 
 
1.45 1.94 1.22 1.68 1.60 
Cash Ratio 
 
0.05 0.13 0.005 0.73 0.94 
Table 8: Liquidity Ratio Analysis 
 Calculation is given in appendices 
 
 
Figure 10: Liquidity Ratio 
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4.3.1  Current Ratio 
 This ratio measures that how much current asset is available to pay out the current liabilities of 
company. Higher ratio indicates good liquidity position. GSK Company’s current ratio decreased 
in year 2007 and 2008 from 6.63 to 4.64 and 2.96. But then the ratio increased in 2009 at 3.11 
which is satisfactory and again fell in 2010 at 2.59 which seem to be quite unstable. 
 
Ratio 2006 2007 2008 2009 2010 
Current Ratio 
 
6.63 4.64 2.96 3.10 2.59 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
-30.02 -36.20 5.01 -   16.58 
 
Comment 
 Ratio should definitely higher than 1. 
 Yet now, GSK’s performance is satisfactory. 
 The threat of the ratio is- it is slowing down at a decreasing rate. 
 
4.3.2  Quick Ratio 
This ratio includes the quick assets that can be easily converted into cash. It measures the 
liquidity position in more conservative way. In 2006 the quick ratio was 1.45. In 2007 it again 
increased to 1.94. Then in 2008 it was the lowest 1.23. The quick ratio is 1.69 in 2009 and 1.60 
in 2010 which indicated better liquidity position of Company. 
 
Ratio 2006 2007 2008 2009 2010 
Quick ratio 
 
1.45 1.94 1.22 1.68 1.60 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
33.03 -36.79 37.39 -4.83 
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Comment 
 Ratio> 1 is required to pay its debt without selling its inventory. 
 GSK is always capable of paying its debts without any stress. 
 
4.3.3  Cash Ratio 
The most conservative measure of liquidity position is cash ratio. Here the cash ratios of GSK 
fluctuate over the first five-year but in year 2010 the ratio is 0.95 which indicate improved 
liquidity position without relying in receivables and GSK can pay its short term debts in cash.  
 
Ratio 2006 2007 2008 2009 2010 
Cash Ratio 
 
0.05 0.13 0.005 0.73 0.94 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
158.35 -95.82 12906.15 29.29 
 
 
Comment 
 Cash ratio should always be less than 1. 
 GSK’s performance is satisfactory. 
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                                                   4.4 Long Term Debt and Solvency Ratio 
Ratio 2006 2007 2008 2009 2010 
Debt to equity 0.32 0.34 0.49 0.46 0.60 
 Debt to total capital 0.24 0.25 0.33 0.32 0.37 
Time interest earned 
ratio 
2.67 17.25 25.23 519.69 653.16 
Fixed charge 
coverage 
-1.16 10.43 19.97 216.08 253.49 
 CFO to Debt 0.06 0.32 0.15 0.84 0.73 
Capital Expenditure 
Ratio 
 
0.25 1.43 1.11 7.60 0.51 
Table 9: Long Term Debt Ratio Analysis 
 Calculation is given in appendices 
 
4.4.1  Debt to Equity Ratio 
This ratio shows how much debt a company has compared to its equity. Higher the ratio 
indicates higher the risk for the company. GSK Company had highest debt to equity ratio in year 
2010. In year 2010, for every Tk. 1 of equity GSK had Tk. 0.60 debt. It means the dependency 
on external financing has increased and riskiness of the firm as well. 
 
Ratio 2006 2007 2008 2009 2010 
Debt to equity 0.32 0.34 0.49 0.46 0.603217172 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
5.47 46.59 -6.34 30.53 
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Figure 11: Debt To equity Ratio 
 
Comment 
 Ratio should remain less than 1. 
 GSK is showing a great prospect in this ratio analysis. 
 
4.4.2  Debt to Capital Ratio 
It measures the proportion of debt on total capital. This ratio shows that how much a firm is 
dependent on external financing. But from the balance sheet we came to learn that GSK 
Company was highly dependent on external financing from year 2008 to 2010 which make the 
company more risky. But in the earlier years the company was less reliable on debt which 
reduces the bankruptcy risk of GSK. 
 
 
Ratio 2006 2007 2008 2009 2010 
Debt to total capital 0.24 0.25 0.33 0.32 0.37 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
4.09 31.19 -4.34 19.04 
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Figure 12: Debt To Total Capital 
 
Comment 
 Lower the fraction is better. 
 GSK showed a tendency to depend more on debt with respect to other years. 
 
 
4.4.3  Time Interest Earned Ratio   
It is a direct measure of ability of paying the interest for a company. This ratio fluctuates over 
five year period. In year 2006, for Tk. 1 interest GSK has Tk. 2.67 EBIT which was satisfactory. 
Then in year 2010 it became highest at Tk. 653.17 EBIT.  
 
Ratio 2006 2007 2008 2009 2010 
Time interest earned 
ratio 
2.67 17.25 25.23 519.69 653.16 
% Change over the period of time 
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Figure 13: Times Interest Earned Ratio 
 
Comment 
 Ratio should always be greater than 1. 
 Higher the fraction shows the strengths. 
 GSK has an extraordinary performance regarding the ratio. 
 
 
4.4.4  Fixed Charge Coverage Ratio 
This ratio measures the ability to pay all fixed charges for a company. Higher the ratio is better. 
In 2010 this ratio was 253.49 which was higher than rest of the years. 
 
Ratio 2006 2007 2008 2009 2010 
Fixed charge 
coverage 
-1.16 10.43 19.97 216.08 253.4915014 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
999.51 91.38 982.002 17.31 
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Figure 14: Fixed Charge Coverage Ratio 
Comment 
 Ratio should always be greater than 1. 
 Higher the fraction shows the strengths. 
 GSK has an extraordinary performance regarding the ratio. 
 
 
4.4.5  CFO to Debt Ratio 
This ratio measures the cash flow generated by the firm to pay debt. Higher the ratio is better. 
CFO to debt ratio was 0.06 in 2006. But it increased to 0.74 in year 2010 compare to 2006, 
which indicates solvency of the company. 
 
Ratio 2006 2007 2008 2009 2010 
CFO to Debt 0.06 0.32 0.15 0.84 0.73 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
0.002 -53.80 474.43 -12.51 
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Figure 15: CFO to Debt 
Comment 
 Higher the ratio is better. 
 The graph shows the increased solvency of GSK. 
 
 
4.4.6  Capital Expenditure Ratio 
This ratio measures the cash flow generated by the firm to pay capital expenditure. In 2005 it 
was 0.79. Then it decreased to 0.25 in 2006. From 2007 it started to increase and in 2009 it was 
7.60 which is satisfactory but again it fell in 2010 to 0.51 dramatically.  
 
Ratio 2006 2007 2008 2009 2010 
Capital Expenditure 
Ratio 
 
0.25 1.43 1.11 7.60 0.514 
% Change over the period of time 
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Figure 16: Capital Expenditure Ratio 
Comment 
 Higher the ratio shows the growth of the company. 
 GSK’s performance can be evaluated as satisfactory. 
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                                                                             4.5 Profitability Analysis 
Ratio 2006 2007 2008 2009 2010 
Gross Margin 19.67 21.56 24.98 31.23 34.20 
Operating Margin -0.71 4.98 11.26 14.28 14.74 
Margin before interest 
and tax 
-0.71 4.98 11.26 14.28 14.74 
Pretax margin -0.61 4.85 10.84 14.51 15.21 
Profit Margin -1.19 2.83 7.57 10.71 11.29 
Return on Assets  
(ROA) 
-1.01 7.40 15.60 25.38 24.18 
Return on Equity 
(ROE) 
-2.23 5.64 15.67 27.28 34.05 
Table 10: Profitability Ratio Analysis 
 Calculation is given in appendices 
 
4.5.1  Gross Margin 
It shows the relationship between sales and COGS. Higher the ratio is better. GSK has stable 
gross margin over five year period. In 2006 the Gross margin was 19.67% and in 2010 it is 
34.20%. So GSK is efficient to manage its’ direct expenses which leads to higher profit. 
Ratio 2006 2007 2008 2009 2010 
Gross Margin 19.67 21.56 24.98 31.23 34.20 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
9.58 15.86 25.01 9.52 
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Figure 17: Gross Margin 
Comment 
 Higher the ratio is better. 
 Trend should be upward sloppy. 
 GSK is continuously striving for the margin year after year. 
 
4.5.2  Operating Margin 
It measures profitability of firm from it’s core business. It is independent from firm’s investing, 
financing and tax position. The operating margin of GSK was decreased in year 2006 to -0.71% 
but then it increased. In 2010 operating margin becomes 14.74% which indicates higher profit 
from core business of GSK. 
 
Ratio 2006 2007 2008 2009 2010 
Operating Margin -0.71 4.98 11.26 14.28 14.74 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
799.81 126.34 26.82 3.24 
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Figure 18: Operating Margin 
Comment 
 Higher the ratio is better. 
 The trend should be upward sloppy. 
 The trend is increasing at a decreasing rate. 
 
4.5.3  Pretax Margin 
Pretax margin measures the profitability which is independent from the impact of tax. Pretax 
margin is highest in year 2010 which is 15.22%. 
 
Ratio 2006 2007 2008 2009 2010 
Pretax margin -0.61 4.85 10.84 14.51 15.21 
% Change over the period of time 
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Figure 19: Pretax Margin 
Comment 
 Higher the ratio is better. 
 Trend should be upward sloppy. 
 GSK is continuously striving for the margin year after year. 
 
4.5.4  Profit Margin 
It measures overall profit margin net of all expenses. Higher the ratio represents better position. 
Profit margin was 3.64% in year 2005. But it decreased in 2006 to -1.19% and then again 
increased. But in recent year 2010 profit margin is 11.29% which indicate the improved position 
of GSK in terms of profitability. 
 
Ratio 2006 2007 2008 2009 2010 
Profit Margin -1.19 2.83 7.57 10.71 11.29 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
338.30 167.07 41.43 5.46 
-0.61 
4.85 
10.84 
14.51 
15.22 
-2
0
2
4
6
8
10
12
14
16
18
2006 2007 2008 2009 2010
Pretax Margin 
 GSK Bangladesh Ltd. Financial Performance Trend Analysis 48 
 
 
Figure 20: Profit Margin 
Comment 
 Higher the ratio is better. 
 The trend should be upward sloppy. 
 The trend is increasing at a decreasing rate. 
 
4.5.5  ROA 
ROA measures the efficiency of firm to utilize its assets to generate revenue and return available 
to the capital providers. GSK had low ROA -1.012 in year 2006 which means asset could not 
utilize properly to generate profit. But gradually ROA of GSK has increased to 25.381 at 2009 
which indicates better utilization of asset in recent years. So capital providers also get higher 
return 
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Figure 21: Return On Assets 
Comment 
 Higher the ratio is better. 
 The trend should be upward sloppy. 
 The trend shows stable position of GSK. 
 
4.5.6  ROE 
Measures the return on total stockholder’s equity and excludes debt in the dominator and uses 
either pretax income or net income. Higher the ratio is the better for the firm. The firm has higher 
ROE in 2010 which is 34.05%. ROE is higher in those years when ROA rises. This firm’s 
shareholders get higher return over the years. 
 
Ratio 2006 2007 2008 2009 2010 
Return on Equity 
(ROE) 
-2.23 5.64 15.67 27.28 34.05 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
352.91 177.83 74.09 24.81 
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Figure 22: Return On Equity 
Comment 
 Higher the ratio is better. 
 12-15% is the average. 
 The trend shows the extraordinary performance of GSK. 
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                                                                  4.6 Operating & Financial Leverage 
Ratio 2006 2007 2008 2009 2010 
 Operating Leverage 
Effect 
-27.67 4.33 2.22 2.19 2.319 
 Financial Leverage 
Effect 
0.60 1.76 1.49 1.33 1.30 
 Total Leverage 
Effect 
-16.54 7.61 3.30 2.92 3.02 
Table 11: Operating & Financial Leverage Ratio Analysis 
 Calculation is given in appendices  
 
 
4.6.1  OLE (Operating Leverage Effect) 
 OLE is a measure of percentage change in income due to percentage change in sales volume. 
When OLE is greater than 1, operating leverage in present. GSK Company has highest OLE in 
year 2007 that is 4.33. It means if sales increase (decrease) by 1%, then operating income will 
increase (decrease) by 4.33%. The OLE of GSK has reduced then gradually. In 2010 OLE is 2.32 
which mean riskiness has reduced. 
Ratio 2006 2007 2008 2009 2010 
Operating Leverage 
Effect 
-27.67 4.33 2.22 2.19 2.31 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
    
115.65 -48.81 -1.43 6.08 
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Figure 23: Operating Leverage Effect 
Comment 
 The ratio should be greater than or equal to 1. 
 GSK stands at the stable position. 
 Extreme higher ratio will lead to destruction. 
 
4.6.2  FLE (Financial Leverage Effect) 
FLE measures for a given change in operating income how much net income will change. GSK 
has highest fixed cost in year 2007 so as FLE. So in year 2007 risk was higher. If operating 
income changes by 1% then net income will change by 1.76%. GSK has lowest FLE in year 
2006 that is 0.60. 
 
Ratio 2006 2007 2008 2009 2010 
Financial Leverage 
Effect 
0.60 1.76 1.49 1.33 1.30 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
193.65 -15.24 -10.33 -2.09 
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Figure 24: Financial Leverage Effect 
 
Comment 
 The ratio should be greater than or equal to 1. 
 GSK stands at the stable position. 
 Extreme higher ratio will lead to destruction. 
 
4.6.3  TLE (Total Leverage Effect) 
It measures the percentage change in net income due to percentage change in sales.  
GSK has highest total leverage in 2007 that is 7.61. But TLE is 2.92 in year 2009. It means the 
firm was more risky in previous years but now risk of the firm has reduced. 
Ratio 2006 2007 2008 2009 2010 
Total Leverage 
Effect 
-16.54 7.61 3.30 2.92 3.02 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
145.98 -56.61 -11.61 3.85 
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Figure 25: Total Leverage Effect 
Comment 
 The ratio should be greater than or equal to 1. 
 GSK stands at the stable position right now than year 2007. 
 Now GSK is comparatively less risky than that off the other year’s TLE. 
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                                                                                               4.7 Investor’s Analysis 
 
RATIO 2006 2007 2008 2009 2010 
EPS -1.43 3.74 11.87 28.88 34.05 
P/E Ratio -95.43 51.60 27.81 25.10 33.17 
Table 12: Investor’s Analysis 
 Calculation is given in appendices 
 
4.7.1  Earning Per Share (EPS) 
Earnings per share ratio (EPS Ratio) are a small variation of return on equity capital ratio and are 
calculated by dividing the net profit after taxes and preference dividend by the total number 
of equity shares. EPS indicates the profitability of GSK. 
 
Ratio 2006 2007 2008 2009 2010 
EPS -1.43 3.74 11.87 28.88 34.05 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
363.38 217.37 143.30 17.90 
 
As gross profit ratio  start to increasing  same way earning per share start to increase  from 2007 
to 2010 company well performed to improved  share holder right. We can see year to GSK 
earning per share increases. So, the company is well managing its profitability compared to the 
industry. 
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Figure 26: Earnings Per Share 
Comment 
 Higher the ratio is better. 
 GSK’s trend is upward sloppy which is a good sign. 
 The trend shows the extraordinary performance of GSK. 
 
4.7.2  Price Earnings Ratio (P/E) 
Price earnings ratio is the ratio between market price per equity share and earnings per share. 
The ratio is calculated to make an estimate of appreciation in the value of a share of a 
company and is widely used by investors to decide whether or not to buy shares in a particular 
company 
 
Ratio 2006 2007 2008 2009 2010 
P/E Ratio -95.43 51.60 27.81 25.10 33.17 
% Change over the period of time 
2006-2007 2007-2008 2008-2009 2009-2010 
154.07 -46.10 -9.71 32.13 
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Over all  price earnings ratio  effect to the  buying  attitude  to the share holder  when P/E ratio is 
high than buyer  discourage to GSK  share  but  company  well performed  every year increase  
their gross profit ratio, profit margin ,earning per share ratio vice versa start to decries P/E ratio. 
Above calculation can recommend GSK start financially stronger more competent than previous 
year from 2007 to 2010 continuously decries show that well position of GSK. 
 
 
Figure 27: P/E Ratio 
Comment 
 Ratio> 20 indicates strong investor confidence & Ratio<12 is likely to grow slowly. 
 No P/E ratio has a fixed meaning good or bad. There is no cut-off for what is high or low. 
 Comparing to the years- 2006 & 2007; GSK’s position is quite stable in the next three 
years. 
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                                                                                         5.0   Conclusion 
Financial performance analysis and management reporting activity is the process of 
understanding the budget preparation process and participation of different departments through 
analysis of reported financial information, particularly annual and quarterly reports. It is the 
selection, evaluation, and interpretation of budgeting data, along with other relevant information, 
to assist in investment and financial decision-making.  
 
Affiliation report helps us to more efficient and more active to gather practical knowledge it 
efficient for practical life.  
Financial statement analysis is an evaluative method of determining the past, current and 
projected performance of a company. One technique is commonly used as part of financial 
statement analysis ‘ratio’ analysis, which calculates statistical relationships between data.  
 
Financial statement analysis enables organizations to assess their current operating performance, 
review the state of the economy and determine how they will perform in the future. 
Understanding that an ounce of prevention is worth a pound of cure, corporate management fully 
supports forecasting activities. 
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                                                                                               5.1  Identified Factors 
 GSK has no long term debt almost depend on their capital. 
 GSK has no over capital because their current asset, fixed asset own asset and not over-
capitalized as its earnings are sufficient to justify a fair return on the amount of share capital 
that has been invested. The total of owned and borrowed capital does not exceed its fixed 
and current assets. 
 GSK is one of the world recognized pharmaceutical company every year increase their sales 
current ratio increase year after year and asset turnover ratio. The current ratio and the 
turnover ratios justify that GSK is not under-trading.  
 GSK is not under-capitalized as well. If the owned capital of GSK was less than the total 
borrowed capital, then it would have been a sign of under capitalization. This would indicate 
that the owned capital of the company is disproportionate to the scale of its operation and 
the business is dependent upon borrowed money and trade creditors.  
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                                                                                               5.2  Recommendation 
 
 MNC objective is to maximize the share holder profit but at 2010, P/E ratio not good. 
 GSK needs to give a check in its Operating expenses specially, Selling and Distribution 
expenses. 
 GSK need to increase market share in pharmaceutical sector and vaccine because it is one 
of the second largest research based company in the world. 
 GSK needs to improvise marketing strategy at pharmaceutical sector because every year 
they lost market share. 
 GSK should think over its standard budgeting policy of paying dividends out of Retained 
earnings because this may lead to an investment crisis in future when GSK might have to 
borrow to meet the investment needs. 
 GSK should oversee whether its Debt-to-Equity ratio is in favor of the Company. A 
rising dependency on debt may create a future liquidity as well as credit-worthiness 
problem. So GSK should make a proper budget plan for further investment. 
 GSK should try to increase their market share. 
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List of DMOs 6
Summary of the key factors 13
GSK’s Market Share & Position 13
GSK’s Market Share & Position 14
Industry Analysis at A Glance
Short Term Activity Ratio Analysis 24
Long Term Activity Ratio Analysis 31
Liquidity Ratio Analysis 34
Long Term Debt Ratio Analysis 37
Profitability Ratio Analysis 44
Operating & Financial Leverage Ratio Analysis 51
Investor’s Analysis 55
05
Serial No.
01
02
03
04
12
06
07
08
09
10
11
Particulars Formula 2006 2007 2008 2009 2010
2006-2007 2007-2008 2008-2009 2009-2010
Inventory Turnover Cost of Goods Sold / Average Inventory 0.55 0.65 0.69 0.86 0.92 19.67 5.95 24.28 6.21
Average No. Days Inventory In Stock 365 / Inventory Turnover 667.58 557.84 526.50 423.64 398.87 -16.44 -5.62 -19.54 -5.85
Receivables Turnover Sales / Average Trade Receivables 2.33 1.86 1.34 1.82 2.08 -20.22 -27.83 36.09 14.26
Average No. Days Receivables Outstanding 365 / Receivables Turnover 156.96 196.75 272.63 200.33 175.33 25.35 38.57 -26.52 -12.48
PayableTurnover Purchase / Average Accounts Payable 0.91 0.91 0.83 1.02 0.82 -0.22 -8.69 23.62 -19.44
Average No. Days Payables Outstanding 365 / Payables Turnover 401.54 402.43 440.73 356.52 442.55 0.22 9.52 -19.11 24.13
Fixed Asset Turnover Sales / Fixed Assets 4.30 4.72 5.49 8.23 9.31 9.78 16.43 49.97 13.07
Total Asset Turnover Sales / Total Assets 1.42 1.49 1.39 1.78 1.64 4.46 -6.81 28.22 -7.70
Curent Ratio Current Assets / Current Liabilities 6.63 4.64 2.96 3.11 2.59 -30.02 -36.21 5.01 -16.59
Quick Ratio (Current Assets - Inventories) / Current Liabilities 1.46 1.94 1.23 1.69 1.60 33.03 -36.80 37.39 -4.83
Cash Ratio (Cash + Marketable Securities) / Current Liabilities 0.05 0.14 0.01 0.73 0.95 158.36 -95.83 12906.15 29.29
Debt to Total Capital Total Debt / Total Capital 0.24 0.25 0.33 0.32 0.38 4.10 31.20 -4.34 19.04
Debt to Equity Total Debt / Total Equity 0.32 0.34 0.49 0.46 0.60 5.48 46.60 -6.35 30.53
Time Interest Earned (TIE) EBIT / Interset Expense 2.67 17.25 25.23 519.69 653.17 545.70 46.29 1959.65 25.68
Fixed Charge Coverage Earing before Fixed Charges & Taxes / Fixed Charges -1.16 10.43 19.97 216.08 253.49 999.52 91.39 982.00 17.31
Capital Expenditure Ratio CFO / Capital Expenditure 0.25 1.43 1.11 7.60 0.51 482.29 -22.73 586.29 -93.23
CFO to Debt CFO / Total Debt 0.06 0.32 0.15 0.84 0.74 0.00 -53.81 474.44 -12.51
Gross Margin Gross Profit / Sales 19.67 21.56 24.98 31.23 34.20 9.59 15.87 25.01 9.53
Operating Margin Operating Profit / Sales -0.71 4.98 11.26 14.28 14.75 799.81 126.35 26.83 3.25
Margin before Interest and Tax EBIT / Sales -0.71 4.98 11.26 14.28 14.75 799.81 126.35 26.83 3.25
Pretax Margin EBT / Sale -0.61 4.85 10.84 14.51 15.22 891.17 123.30 33.92 4.86
Profit Margin Net Income /Sales -1.19 2.83 7.57 10.71 11.29 338.31 167.07 41.44 5.46
Return on Assets (ROA) ( Net Income + After Tax Interest ) / Avg Total Asset -1.01 7.40 15.61 25.38 24.19 831.04 110.92 62.62 -4.70
Return on Equity (ROE) Pretax Income / AVG Sharehoder's Equity -2.23 5.64 15.67 27.28 34.05 352.91 177.84 74.09 24.82
(1) Activity Analysis
(i) Short-Term (Operating) Activity Ratios
(ii) Long-Term (Investment) Activity Ratios
(2) Liquidity Analysis
(3) Long term Debt and Solvency Ratio
(ii) Return on Investment
(i) Debt Covenants
(ii) Capital Expenditure and CFO to Debt Ratio
(4) Profitability Analysis
(i) Return on Sales
(1) Activity Analysis
(i) Short-Term (Operating) Activity Ratios
(ii) Long-Term (Investment) Activity Ratios
(2) Liquidity Analysis
% Change over the period of time
(3) Long term Debt and Solvency Ratio
(i) Debt Covenants
(ii) Capital Expenditure and CFO to Debt Ratio
(4) Profitability Analysis
(i) Return on Sales
(ii) Return on Investment
Operating Leverage Effect (OLE) Gross Profit / EBIT or Operating Income -27.67 4.33 2.22 2.19 2.32 115.66 -48.81 -1.43 6.08
Financial Leverage Effect (DLE) Operating Income / Net Income 0.60 1.76 1.49 1.33 1.31 193.66 -15.25 -10.33 -2.10
Total Leverage Effect (TLE) Gross Profit / Net Income -16.54 7.61 3.30 2.92 3.03 145.99 -56.62 -11.61 3.86
Earning Per Share (EPS) EPS= (EAT − Preference Dividend) / No. of Common Shares -1.42 3.74 11.87 28.88 34.05 363.38 217.38 143.30 17.90
Price Earning Ratio (P/E) Market Price Per Share/ EPS -95.42 51.60 27.81 25.11 33.17 154.08 -46.11 -9.72 32.13
(6) Investor's Analysis
(5) Operating and Financial Leverage
(6) Investor's Analysis
(5) Operating and Financial Leverage
